JP2011520918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520918A5 JP2011520918A5 JP2011509783A JP2011509783A JP2011520918A5 JP 2011520918 A5 JP2011520918 A5 JP 2011520918A5 JP 2011509783 A JP2011509783 A JP 2011509783A JP 2011509783 A JP2011509783 A JP 2011509783A JP 2011520918 A5 JP2011520918 A5 JP 2011520918A5
- Authority
- JP
- Japan
- Prior art keywords
- relaxin
- heart failure
- treatment
- subject
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003743 Relaxin Human genes 0.000 claims description 86
- 108090000103 Relaxin Proteins 0.000 claims description 86
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 33
- 206010013975 Dyspnoeas Diseases 0.000 claims description 28
- 208000000059 Dyspnea Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 16
- 230000002861 ventricular Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 238000001802 infusion Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000035488 systolic blood pressure Effects 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 239000002171 loop diuretic Substances 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 206010037368 Pulmonary congestion Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000002642 intravenous therapy Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12788908P | 2008-05-16 | 2008-05-16 | |
| US61/127,889 | 2008-05-16 | ||
| US19054508P | 2008-08-28 | 2008-08-28 | |
| US61/190,545 | 2008-08-28 | ||
| US20124008P | 2008-12-08 | 2008-12-08 | |
| US61/201,240 | 2008-12-08 | ||
| US16433309P | 2009-03-27 | 2009-03-27 | |
| US61/164,333 | 2009-03-27 | ||
| PCT/US2009/044249 WO2009140659A2 (en) | 2008-05-16 | 2009-05-15 | Method of treating dyspnea associated with acute heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012200728A Division JP5638044B2 (ja) | 2008-05-16 | 2012-09-12 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520918A JP2011520918A (ja) | 2011-07-21 |
| JP2011520918A5 true JP2011520918A5 (enExample) | 2012-11-01 |
| JP5651586B2 JP5651586B2 (ja) | 2015-01-14 |
Family
ID=40834101
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509783A Expired - Fee Related JP5651586B2 (ja) | 2008-05-16 | 2009-05-15 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2012200728A Expired - Fee Related JP5638044B2 (ja) | 2008-05-16 | 2012-09-12 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2014165276A Expired - Fee Related JP5875646B2 (ja) | 2008-05-16 | 2014-08-14 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2015201153A Pending JP2016053040A (ja) | 2008-05-16 | 2015-10-09 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012200728A Expired - Fee Related JP5638044B2 (ja) | 2008-05-16 | 2012-09-12 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2014165276A Expired - Fee Related JP5875646B2 (ja) | 2008-05-16 | 2014-08-14 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
| JP2015201153A Pending JP2016053040A (ja) | 2008-05-16 | 2015-10-09 | 急性心不全に伴う呼吸困難のリラキシンによる治療 |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US8415301B2 (enExample) |
| EP (2) | EP2829280A1 (enExample) |
| JP (4) | JP5651586B2 (enExample) |
| CN (3) | CN102036679A (enExample) |
| AR (1) | AR071810A1 (enExample) |
| AU (1) | AU2009246114B2 (enExample) |
| BR (1) | BRPI0913011A2 (enExample) |
| CA (1) | CA2724540C (enExample) |
| CR (1) | CR11749A (enExample) |
| CY (1) | CY1116925T1 (enExample) |
| DK (1) | DK2288373T3 (enExample) |
| EA (2) | EA022948B1 (enExample) |
| ES (1) | ES2546287T3 (enExample) |
| GB (2) | GB2459983B (enExample) |
| HK (1) | HK1202054A1 (enExample) |
| HR (1) | HRP20150845T1 (enExample) |
| HU (1) | HUE025483T2 (enExample) |
| IL (3) | IL208992A (enExample) |
| MA (1) | MA32389B1 (enExample) |
| MX (1) | MX2010012450A (enExample) |
| MY (2) | MY159803A (enExample) |
| NZ (3) | NZ701038A (enExample) |
| PL (1) | PL2288373T3 (enExample) |
| PT (1) | PT2288373E (enExample) |
| SG (2) | SG191587A1 (enExample) |
| SI (1) | SI2288373T1 (enExample) |
| TW (1) | TWI386202B (enExample) |
| UA (1) | UA99953C2 (enExample) |
| WO (1) | WO2009140659A2 (enExample) |
| ZA (1) | ZA201007449B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009246112B2 (en) * | 2008-05-16 | 2013-05-02 | Corthera, Inc. | Method of treating chronic heart failure |
| US8415301B2 (en) * | 2008-05-16 | 2013-04-09 | Corthera, Inc. | Method of treating dyspnea associated with acute heart failure by administering H2 relaxin |
| KR101800040B1 (ko) * | 2010-03-10 | 2017-11-21 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 릴랙신을 사용한 아쿠아포린의 조절 |
| JP5899213B2 (ja) | 2010-08-06 | 2016-04-06 | マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ | 腎機能不全のバイオマーカーとしてのパールカン |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| PE20140160A1 (es) * | 2010-08-17 | 2014-02-08 | Ambrx Inc | Polipeptidos de relaxina modificados y sus usos |
| AU2012280474A1 (en) * | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| WO2013059879A1 (en) * | 2011-10-26 | 2013-05-02 | Howard Florey Institute Of Experimental Physiology And Medicine | Compositions and methods for the treatment of fibrosis and fibrotic diseases |
| JP6562632B2 (ja) * | 2012-02-14 | 2019-08-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 心血管疾患および他の状態のためのパラクリン遺伝子の全身送達および制御された発現 |
| US9452973B2 (en) | 2012-05-04 | 2016-09-27 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Modulators of the relaxin receptor 1 |
| CN110840890A (zh) | 2012-10-26 | 2020-02-28 | 凯西制药公司 | 用于在心力衰竭中控制血压和减轻呼吸困难的方法 |
| CN105431145B (zh) | 2013-04-05 | 2019-12-10 | Sc医药品有限公司 | 用于呋塞米的皮下施用的药物制剂 |
| US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| HK1226581A1 (zh) * | 2014-02-03 | 2017-09-29 | Novartis Ag | 用於输液器上的过滤器 |
| EP2946788A1 (en) * | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
| JP6820748B2 (ja) * | 2014-06-13 | 2021-01-27 | ノバルティス アーゲー | Ｇｄｆ−１５を減少させるためのセレラキシンの使用 |
| US11161891B2 (en) | 2015-12-09 | 2021-11-02 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
| CN108697330B (zh) | 2016-02-12 | 2022-07-15 | 心脏起搏器股份公司 | 用于患者监视的系统和方法 |
| SG10201912034UA (en) | 2017-02-08 | 2020-02-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| US11832970B2 (en) | 2017-07-26 | 2023-12-05 | Cardiac Pacemakers, Inc. | Worsening heart failure stratification |
| CN107335051A (zh) * | 2017-08-18 | 2017-11-10 | 温州医科大学附属第医院 | 一种保护慢性心衰肾功能的药物组合物 |
| ES3041602T3 (en) | 2018-12-10 | 2025-11-13 | Sq Innovation Ag | Pharmaceutical compositions of furosemide and uses thereof |
| ES3058386T3 (es) | 2019-01-04 | 2026-03-10 | Sq Innovation Ag | Composiciones farmacéuticas de furosemida |
| EP3906020B1 (en) | 2019-01-04 | 2025-12-31 | SQ Innovation AG | Pharmaceutical compositions of torsemide and their uses |
| AU2020214314B2 (en) | 2019-01-31 | 2025-09-18 | Scpharmaceuticals Inc. | Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same |
| JP2025528469A (ja) | 2022-08-31 | 2025-08-28 | リラクセラ ファルマツォイティッシュ ゲゼルシャフト エムベーハー ウント コー． カーゲー | 免疫抑制薬及び処置方法 |
| EP4791358A1 (en) | 2023-09-15 | 2026-08-19 | Relaxera Pharmazeutische Gesellschaft mbH & Co. KG | Relaxin medication |
| CN121837268B (zh) * | 2026-03-12 | 2026-06-16 | 西安建筑科技大学 | 一种基于渐进性风险排序的尘肺病早期精细化筛查方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023321A (en) * | 1982-12-13 | 1991-06-11 | Howard Florey Institute Of Experimental Physiology & Medicine | Molecular cloning and characterization of a further gene sequence coding for human relaxin |
| US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
| US5478807A (en) | 1991-08-19 | 1995-12-26 | Genentech, Inc. | Use of relaxin in the treatment of bradycardia |
| CA2165781C (en) | 1993-06-21 | 2007-02-13 | Tim Breece | Process for producing relaxin |
| CA2145515A1 (en) * | 1993-07-27 | 1995-02-09 | Mario Bigazzi | Use of relaxin as therapeutic or preventing agent |
| US5760069A (en) | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
| US5811395A (en) * | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
| ES2187667T3 (es) * | 1995-08-15 | 2003-06-16 | Connetics Corp | Uso de relaxina para estimular angiogenesis. |
| ATE362770T1 (de) * | 2000-02-09 | 2007-06-15 | Bas Medical Inc | Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen |
| DE10155843A1 (de) * | 2000-11-16 | 2003-01-30 | Immundiagnostik Ag | Verfahren zur Prognose und Diagnose von Herzinsuffizienz |
| US20050113286A1 (en) | 2002-03-18 | 2005-05-26 | Schreiner George F. | Methods for treating congestive heart failure |
| US7878978B2 (en) * | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
| EP1729817B1 (en) * | 2004-03-30 | 2014-03-05 | Industry-Academic Cooperation Foundation | Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin |
| US20060264367A1 (en) | 2005-05-21 | 2006-11-23 | Howard Florey Institute | Prevention of fibrosis following cardiac injury |
| WO2007008907A2 (en) * | 2005-07-11 | 2007-01-18 | Abbott Laboratories | Methods for determining how to treat congestive heart failure |
| CA2693651A1 (en) | 2007-07-12 | 2009-01-15 | Ronen Shemesh | Bioactive peptides and method of using same |
| AU2009246112B2 (en) | 2008-05-16 | 2013-05-02 | Corthera, Inc. | Method of treating chronic heart failure |
| US8415301B2 (en) * | 2008-05-16 | 2013-04-09 | Corthera, Inc. | Method of treating dyspnea associated with acute heart failure by administering H2 relaxin |
-
2009
- 2009-05-15 US US12/992,356 patent/US8415301B2/en not_active Expired - Fee Related
- 2009-05-15 GB GB0908432A patent/GB2459983B/en not_active Expired - Fee Related
- 2009-05-15 US US12/467,214 patent/US8053411B2/en not_active Expired - Fee Related
- 2009-05-15 TW TW098116328A patent/TWI386202B/zh not_active IP Right Cessation
- 2009-05-15 BR BRPI0913011A patent/BRPI0913011A2/pt not_active IP Right Cessation
- 2009-05-15 PL PL09747740T patent/PL2288373T3/pl unknown
- 2009-05-15 EP EP14167842.5A patent/EP2829280A1/en not_active Withdrawn
- 2009-05-15 HU HUE09747740A patent/HUE025483T2/en unknown
- 2009-05-15 SI SI200931246T patent/SI2288373T1/sl unknown
- 2009-05-15 CA CA2724540A patent/CA2724540C/en not_active Expired - Fee Related
- 2009-05-15 NZ NZ701038A patent/NZ701038A/en not_active IP Right Cessation
- 2009-05-15 SG SG2013038260A patent/SG191587A1/en unknown
- 2009-05-15 DK DK09747740.0T patent/DK2288373T3/en active
- 2009-05-15 EP EP09747740.0A patent/EP2288373B1/en active Active
- 2009-05-15 ES ES09747740.0T patent/ES2546287T3/es active Active
- 2009-05-15 JP JP2011509783A patent/JP5651586B2/ja not_active Expired - Fee Related
- 2009-05-15 EA EA201001771A patent/EA022948B1/ru not_active IP Right Cessation
- 2009-05-15 SG SG10201609580YA patent/SG10201609580YA/en unknown
- 2009-05-15 MY MYPI2010005049A patent/MY159803A/en unknown
- 2009-05-15 PT PT97477400T patent/PT2288373E/pt unknown
- 2009-05-15 WO PCT/US2009/044249 patent/WO2009140659A2/en not_active Ceased
- 2009-05-15 CN CN2009801177504A patent/CN102036679A/zh active Pending
- 2009-05-15 UA UAA201012879A patent/UA99953C2/uk unknown
- 2009-05-15 EA EA201500552A patent/EA201500552A1/ru unknown
- 2009-05-15 NZ NZ598709A patent/NZ598709A/xx not_active IP Right Cessation
- 2009-05-15 AR ARP090101762A patent/AR071810A1/es unknown
- 2009-05-15 CN CN201310127326.6A patent/CN103212063B/zh not_active Expired - Fee Related
- 2009-05-15 GB GB0918132A patent/GB2462221B/en not_active Expired - Fee Related
- 2009-05-15 HR HRP20150845TT patent/HRP20150845T1/hr unknown
- 2009-05-15 MX MX2010012450A patent/MX2010012450A/es active IP Right Grant
- 2009-05-15 CN CN201610565105.0A patent/CN106177914A/zh active Pending
- 2009-05-15 AU AU2009246114A patent/AU2009246114B2/en not_active Ceased
- 2009-05-15 NZ NZ589009A patent/NZ589009A/en not_active IP Right Cessation
-
2010
- 2010-10-19 ZA ZA2010/07449A patent/ZA201007449B/en unknown
- 2010-10-22 CR CR11749A patent/CR11749A/es unknown
- 2010-10-28 IL IL208992A patent/IL208992A/en not_active IP Right Cessation
- 2010-12-10 MA MA33418A patent/MA32389B1/fr unknown
-
2011
- 2011-05-30 HK HK15102533.3A patent/HK1202054A1/en unknown
- 2011-09-23 US US13/242,012 patent/US8372809B2/en not_active Expired - Fee Related
-
2012
- 2012-09-12 JP JP2012200728A patent/JP5638044B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-04 US US13/734,301 patent/US9066916B2/en not_active Expired - Fee Related
- 2013-03-05 US US13/784,963 patent/US9205132B2/en not_active Expired - Fee Related
- 2013-09-02 IL IL228244A patent/IL228244A/en not_active IP Right Cessation
- 2013-11-28 MY MYPI2013004312A patent/MY158327A/en unknown
-
2014
- 2014-08-14 JP JP2014165276A patent/JP5875646B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-28 US US14/723,701 patent/US9579363B2/en not_active Expired - Fee Related
- 2015-09-18 CY CY20151100824T patent/CY1116925T1/el unknown
- 2015-10-09 JP JP2015201153A patent/JP2016053040A/ja active Pending
-
2016
- 2016-08-18 IL IL247351A patent/IL247351A0/en unknown
-
2017
- 2017-01-23 US US15/412,447 patent/US20170151311A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miller et al. | Afterload reduction therapy with nitroprusside in severe aortic regurgitation: improved cardiac performance and reduced regurgitant volume | |
| Taguchi et al. | Effects of enhanced external counterpulsation on hemodynamics and its mechanism relation to neurohumoral factors | |
| RU2627842C2 (ru) | Средство для улучшения диастолической функции левого желудочка | |
| Weir | Diltiazem: ten years of clinical experience in the treatment of hypertension | |
| JP3336331B2 (ja) | 新生内膜形成、再狭窄、および動脈硬化の予防および処置のための薬剤としてのデスアスパラギン酸アンジオテンシンｉを使用する薬学的組成物 | |
| Figueras et al. | Prognostic implications of early spontaneous angina after acute transmural myocardial infarction | |
| Burckhartt et al. | Coronary artery slow flow associated with angina pectoris and hypotension: a case report | |
| Cantelli et al. | Comparison of acute haemodynamic effects of nifedipine and isosorbide dinitrate in patients with heart failure following acute myocardial infarction | |
| Yeh et al. | Sodium nitroprusside as a coronary vasodilator in man: I. Effect of intracoronary sodium nitroprusside on coronary arteries, angina pectoris, and coronary blood flow | |
| Bauer et al. | Rapid reduction of severe hypertension with minoxidil | |
| CN119156218A (zh) | 用于治疗心源性休克前期和心源性休克的含有istaroxime的静脉内制剂 | |
| WO2013030564A1 (en) | Vascular treatments | |
| Aronow | Ten key points from the American College of Cardiology Foundation/American Heart Association 2011 expert consensus document on hypertension in the elderly | |
| Johnson et al. | Treatment of shock in myocardial infarction | |
| Chandraratna et al. | Use of Nitroglycerin Ointment in Congestive Heart Failure: Results of Acute and Chronic Therapy | |
| Mehta et al. | Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure. | |
| Lee et al. | Cardiovascular collapse following orthoclone OKT3 administration: a case report | |
| Koliopoulos et al. | Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension | |
| Weiss et al. | The Never-Ending Story of Complicated Hypertension | |
| Houde et al. | Indapamide for out-patient treatment of hypertension: modifications in serum catecholamine levels | |
| Kramer et al. | Controlled trial of captopril for heart failure: Effects on hemodynamics, scintigraphy and exercise tolerance | |
| Shin et al. | REAL WORLD EFFICACY OF NEBIVOLOL IN COMBINATION WITH RENIN ANGIOTENSIN SYSTEM BLOCKADE AND/OR CALCIUM ANTAGONIST, A SUB-STUDY OF PROSPECTIVE, MULTICENTER OBSERVATIONAL STUDY | |
| Hill et al. | Orthostatic Hypotension following Right Ventricular Myocardial Infarction Corrected with Mineralocorticoid Therapy | |
| Cody et al. | Captopril pharmacokinetics in chronic heart failure: correlation with acute hemodynamic and hormonal response | |
| Sharp et al. | Nesiritide for treatment of heart failure due to right ventricular dysfunction |